Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Y. Michael Shim, MD
Study ID
NCT06856525
Phase
PHASE2/PHASE3
Status
Recruiting

Conditions

  • Electronic Cigarette Related Lung Damage

Eligibility Criteria

Sex
ALL
Age
18 Years - 35 Years
Healthy Volunteers
Accepted

Interventions

  • Hyperpolarized xenon 129 — DRUG
    Determine the impact of e-cigarette use on pulmonary gas exchange capacity in interstitial tissues and capillaries using hyperpolarized xenon-129 MRI.
  • Cardiopulmonary Stress Test — DIAGNOSTIC_TEST
    Exercise stress test to evaluate cardiac and pulmonary fitness.
  • Pulmonary Function Test — DIAGNOSTIC_TEST
    Standard clinic pulmonary function test to evaluate lung function
  • Chest CT — DIAGNOSTIC_TEST
    Clinical standard chest computer tomography to evaluate any lung tissue scars or air movement.

Study Details

A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of electronic cigarette use on pulmonary gas exchange capacity and then corroborate the Hyperpolarized Xenon MRI (HXeMRI) results with the cardiopulmonary stress test at the initial visit and a follow-up visit 12 months later.

Key Dates

Start date
Dec 19, 2024
Status verified
Mar 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2032

Study Design

Enrollment
80 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Other: Healthy Participants
    Young, healthy subjects without any lung disease or other inflammatory diseases.
  • Experimental: eCig user
    Young, otherwise healthy subjects who have used electronic cigarettes for at least 6 months past year.

Primary Outcome Measure

Comparison between e-cig user vs. healthy participants at baseline and 12 month later [ Time Frame: baseline and 12 month follow-up ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Duke UniversityDurhamNorth Carolina27705
Cody Blanton, BS
919-668-7575
Joseph Mammarappallil, MD (PRINCIPAL_INVESTIGATOR)
University of VirginiaCharlottesvilleVirginia22908
Yun M Shim, MD
434-924-5210
Roselove N Asare, MA
434-243-6074
Yun M Shim, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Durham, NC